We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Renovacor, Inc. (“Renovacor” or the “Company”) (NYSE:RCOR), in connection with the proposed acquisition of the Company by Rocket Pharmaceuticals, Inc. (“Rocket Pharmaceuticals”) (NASDAQ: RCKT).  Under the terms of the merger agreement, the Company’s shareholders will receive 0.1676 shares of Rocket Pharmaceuticals common stock for each Renovacor share owned, representing implied per-share merger consideration of approximately $2.34 based upon Rocket Pharmaceuticals’ September 19, 2022 closing price of $13.97.

Weiss Law is investigating whether (i) Renovacor’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the per-share merger consideration adequately compensates Renovacor’s shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.